Form DEFA14A LIPELLA PHARMACEUTICALS
Lipella Pharmaceuticals Inc. (LIPO)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
LIPO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LIPO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LIPO alerts
High impacting Lipella Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
LIPO
News
- Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus [Yahoo! Finance]Yahoo! Finance
- Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen PlanusGlobeNewswire
- Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group [Yahoo! Finance]Yahoo! Finance
- Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose GroupGlobeNewswire
- Lipella Pharmaceuticals Third Quarter 2024 Earnings: US$1.29 loss per share (vs US$1.84 loss in 3Q 2023) [Yahoo! Finance]Yahoo! Finance
LIPO
Sec Filings
- 12/20/24 - Form 8-K
- 12/10/24 - Form 8-K
- 12/6/24 - Form DEFA14A
- LIPO's page on the SEC website